Results 201 to 210 of about 8,868 (210)

CD276 is differentially expressed in glioblastoma.

Glioblastoma is difficult to treat and patients are often provided poor prognosis (1), indicating a requirement for therapeutic target identification and drug development. Differentially expressed genes represent by definition among the most promising targets for the development of novel chemotherapies (2, 3).
openaire   +1 more source

Abstract 6446: Yap1 and CD276/B7-H3: key players in Sex-biased SHH medulloblastoma immune evasion

Cancer Research
The molecular mechanisms driving sex disparities in cancer prevalence, progression, and treatment outcomes represent a crucial yet understudied area with significant implications for cancer therapy. Medulloblastoma (MB), exhibits a pronounced sex bias in
Nourhan Abdelfattah, Sivaraman Natarajan, H. N. Tran, Thomas Wong, Jose Maldonado, Rachael McMinimy, Hannah Borland, Shu-hsia Chen, Fernando Camargo, James Olson, Joshy George, Kyuson Yun   +11 more
semanticscholar   +1 more source

B7H3 (CD276) regulation of myeloid cell differentiation in pulmonary fibrosis

The Journal of Immunology
Abstract Myeloid-derived suppressor cells (MDSCs) are induced in cancer and fibrosis, while absent in healthy tissues. The expansions of MDSC are correlated with disease severity and lung function deterioration in the latter. B7H3 induced in lung fibrosis causes the recruitment of MDSCs.
openaire   +1 more source

Monoclonal Antibody Against Peptide CD276

Hybridoma, 2012
openaire   +1 more source

CD276 Immature Glycosylation Drives Colorectal Cancer Aggressiveness and T-cell Mediated Immune Escape

bioRxiv
Janine Soares, Dylan Ferreira, A. Miranda, Martina Gonçalves, Marta Relvas-Santos, Andreia Brandão, Paula Paulo, Sofia Cotton, Rui Freitas, Mariana Magalhães, Eduardo Ferreira, Beatriz Marinho-Santos, Luís Pedro Afonso, André M N Silva, Carlos Palmeira, Francisco Amado, Andreia Peixoto, L. Santos, J. Ferreira   +18 more
semanticscholar   +1 more source

The inhibitory effects of nimotuzumab on CD276 expression and immune escape in head and neck squamous cell carcinoma: Insights into anticancer mechanisms.

International Immunopharmacology
Minwan Hu, Borui Tang, Di Zhang, Xuhong Wang, Xiuli Zhao   +4 more
semanticscholar   +1 more source

Reply to the comment on "Clinicopathological features and prognostic value of CD276 expression in head and neck cancer: A meta-analysis".

American Journal of Otolaryngology
Ziyu Chen, Hang Su, Juanjuan Hao, Fenghua Zhang   +3 more
semanticscholar   +1 more source

CD276 PREDICTS A POOR RESPONSE TO IMMUNE CHECKPOINT BLOCKAGE IN UROTHELIAL CARCINOMA VIA TUMOR MICROENVIRONMENT REMODELING AND TGF-B SIGNALING

Urologic oncology: Seminars and original investigations
Jack Korleski, Fabrice Lucien-Matteoni, Jacob Orme, R. Lavoie   +3 more
semanticscholar   +1 more source

Control of CD276 by NOD2.

openaire   +1 more source

637 Two targets – two signals: dual bispecific antibody therapy targeting CD276 and FAP by engaging CD3 and CD28 for solid tumor immunotherapy

Regular and Young Investigator Award Abstracts
I. Hagelstein, S. Hörner, Martin Pflügler, Carolin Walker, Stefanie Müller, Christian M Schuerch, J. S. Heitmann, G. Jung, H. R. Salih   +8 more
semanticscholar   +1 more source